25 matches for your search in the start-up spotlight
rss
Refoxy is the first biotech company purposely developing FOXO3 activators to leverage the therapeutic effects related to this master regulator of biological homeostasis. Refoxy’s discovery platform, F.act finder (FOXO activator finder), delivers molecules that specifically modulate FOXO3 and ...
HAYA Therapeutics is a precision medicines company developing programmable therapeutics targeting regulatory RNAs derived from the dark genome, a cell information processing unit, to reprogram pathological cell states for a broad range of diseases, including cardiovascular disease and cancer. The ...
Rewind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis or nerve injuries. A common feature of these illnesses is the loss of the myelin sheath, ...
Bright Peak is a privately held biotechnology company based in San Diego, CA and Basel, Switzerland developing innovative cytokine therapeutics that are uniquely engineered to precisely tune and control desired biological properties. Using its proprietary Enhanced Design and Combine (EDC) ...
NextImmune focuses on the research and development of a new generation of immunosuppressive drugs for autoimmune diseases and Organ Transplantation - with objectives of high efficacy, good safety without adverse effects as known from conventional immunosuppressants.
rnatics develops therapeutics that target disease-causing RNAs in tissue macrophages, which provide tremendous therapeutic opportunities for multiple diseases. Our Vision: To employ the unique natural phagocytic properties of tissue resident macrophages as an effective means of delivery to gain ...
Kojin Therapeutics is the first biopharmaceutical company using a proprietary approach to cell state and ferroptosis biology to develop novel, targeted therapeutics for diseases of high unmet need. Founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan and Vasanthi Viswanathan, Kojin is ...
EXCIVA GmbH TARGETED DRUG RESCUE (TDR) There are about 3,000 drugs that have been approved by at least one country in this world. Just a handful of drugs received approval prior to the creation of the modern FDA in 1938, including Merck's morphine in 1827 and aspirin in 1899. FDA approved 1,453 ...
Eisbach develops novel drugs that disrupt molecular machines essential to tumors with defined genetic vulnerabilities in the context of DNA damage and repair (DDR). Its proprietary platform creates targeted therapies that exploit disease-relevant vulnerabilities. By shutting off the machine’s ...
Bright Peak is a privately held biotechnology company based in San Diego, CA and Basel, Switzerland developing innovative cytokine therapeutics that are uniquely engineered to precisely tune and control desired biological properties. Using its proprietary Enhanced Design and Combine (EDC) ...
